Sort   by:  
 Page size 
UnknownBortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Not available
S-EPMC3577952 | biostudies-literature
UnknownPhase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Not available
S-EPMC4658453 | biostudies-literature
UnknownPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Not available
S-EPMC3518729 | biostudies-literature
UnknownClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
Not available
S-EPMC3731981 | biostudies-literature
UnknownRandomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Not available
S-EPMC5562170 | biostudies-literature
UnknownCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Not available
S-EPMC6127025 | biostudies-literature
UnknownEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Not available
S-EPMC3918538 | biostudies-literature
UnknownPharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Not available
S-EPMC6274593 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownDeferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial.
Not available
S-EPMC10448368 | biostudies-literature
Sort   by:  
 Page size